Clinical features and therapy of double-hit and double-expressor lymphomas
- 作者: Baryakh E1,2, Misyurina A3, Kovrigina A3, Obukhova T3, Kravchenko S3, Magomedova A3, Zingerman B3, Misyurina E1, Poteshkina N1,2, Lysenko M1, Vorobev A3
-
隶属关系:
- City Clinical Hospital №52 of the Department of Health of Moscow
- N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation
- Hematology Research Center of the Ministry of Health of the Russian Federation
- 期: 卷 18, 编号 5 (2016)
- 页面: 22-30
- 栏目: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/27106
- ID: 27106
如何引用文章
全文:
详细
作者简介
E Baryakh
City Clinical Hospital №52 of the Department of Health of Moscow; N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation
Email: ebaryakh@gmail.com
канд. мед. наук, врач-гематолог отд-ния гематологии и высокодозной химиотерапии ГБУЗ ГКБ №52, доц. каф. общей терапии ФДПО ФГБОУ ВО РНИМУ им. Н.И.Пирогова 123182, Russian Federation, Moscow, ul. Pekhotnaia, d. 3; 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1
A Misyurina
Hematology Research Center of the Ministry of Health of the Russian Federationканд. мед. наук, науч. сотр. науч.-клин. отд-ния химиотерапии гемобластозов ФГБУ ГНЦ 125167, Russian Federation, Moscow, Novyi Zykovskii pr., d. 4
A Kovrigina
Hematology Research Center of the Ministry of Health of the Russian Federationд-р биол. наук, зав. патологоанатомическим отд-нием ФГБУ ГНЦ 125167, Russian Federation, Moscow, Novyi Zykovskii pr., d. 4
T Obukhova
Hematology Research Center of the Ministry of Health of the Russian Federationканд. мед. наук, зав. науч.-клин. лаб. кариологии ФГБУ ГНЦ 125167, Russian Federation, Moscow, Novyi Zykovskii pr., d. 4
S Kravchenko
Hematology Research Center of the Ministry of Health of the Russian Federationканд. мед. наук, зав. науч.-клин. отд-нием химиотерапии гемобластозов ФГБУ ГНЦ 125167, Russian Federation, Moscow, Novyi Zykovskii pr., d. 4
A Magomedova
Hematology Research Center of the Ministry of Health of the Russian Federationд-р мед. наук, вед. науч. сотр. науч.-клин. отд-ния химиотерапии гемобластозов ФГБУ ГНЦ 125167, Russian Federation, Moscow, Novyi Zykovskii pr., d. 4
B Zingerman
Hematology Research Center of the Ministry of Health of the Russian Federationзав. отд. информационных технологий ФГБУ ГНЦ 125167, Russian Federation, Moscow, Novyi Zykovskii pr., d. 4
E Misyurina
City Clinical Hospital №52 of the Department of Health of Moscowканд. мед. наук, рук. гематологической службы ГБУЗ ГКБ №52 123182, Russian Federation, Moscow, ul. Pekhotnaia, d. 3
N Poteshkina
City Clinical Hospital №52 of the Department of Health of Moscow; N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federationд-р мед. наук, проф., зав. каф. общей терапии ФДПО ФГБОУ ВО РНИМУ им. Н.И.Пирогова 123182, Russian Federation, Moscow, ul. Pekhotnaia, d. 3; 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1
M Lysenko
City Clinical Hospital №52 of the Department of Health of Moscowд-р мед. наук, глав. врач ГБУЗ ГКБ №52 123182, Russian Federation, Moscow, ul. Pekhotnaia, d. 3
A Vorobev
Hematology Research Center of the Ministry of Health of the Russian Federationакад. РАН, д-р мед. наук, проф., глав. науч. сотр. науч.-клин. отд-ния химиотерапии гемобластозов ФГБУ ГН 125167, Russian Federation, Moscow, Novyi Zykovskii pr., d. 4
参考
- Kluin P.M, Harris N.L, Stein H et al. B-cell lymphoma, unclassifiable with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma in Who Classification of tumors of haematopoietic and lymphoid tissues. Ed. S.H. Swerdlow, E. Campo, N.L. Harris et al. 2008; 265-6.
- Subar M, Neri A, Inghirami G et al. Frequent c - myc oncogne activation and infrequent presense of Epstein-Barr virus genome in AIDS-associated lymphoma. Blood 1988; 72: 667-71.
- Johnson N.A, Savage K.J, Ludkovski O et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 2009; 114: 2273-9.
- Le Gouill S, Talmant P, Touzeau C et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica 2007; 92: 1335-42.
- Petrich A.M, Gandhi M, Jovanovic B et al. Impact of induction regimen and stem cell transplantation on outcomes in double - hit lymphoma: a multicenter retrospective analysis. Blood 2014; 124 (15): 2354-61.
- Greenwood M, Armytage T, Fay K. Outcomes of allogeneic stem cell transplantation for non - Hodgkin lymphoma with concurrent MYC and BCL2 translocations: a single center retrospective analysis. Hematol Oncol 2013; 3 (Suppl. 1): 103.
- Kanungo A, Medeiros L.J, Abruzzo L.V, Lin P. Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis. Modern Pathology 2006; 19: 25-33.
- Tomita N, Tokunaka M, Nakamura N et al. Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations. Haematologica 2009; 94 (7): 935-43.
- Li S, Lin P, Fayad L.E et al. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod Pathol 2012; 25 (1): 145-56.
- Niitsu N, Okamoto M, Miura I, Hirano M. Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia 2009; 23: 777-83.
- Snuderl M, Kolman O.K, Chen Y.B et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol 2010; 34 (3): 327-40.
- Oki Y, Noorani M, Davis R.E et al. Double hit lymphoma: M.D.Anderson Experince. Blood 2013; 122 (21): 1776.
- Sun H, Savage K, Karsan A. Outcome of patients wits double - hit lymphomas treated with CODOX-M/IVAC + R followed by hematopoietic stem cell transplantation in British Columbia. Blood 2013; 122 (21): 1788.
- Leucci E, Cocco M, Onnis A et al. MYC translocation - negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation J Pathol 2008; 216 (4): 440-50.
- Onnis A, De Falco G, Antonicelli G et al. Аlteration of microRNAs regulated by c-MYC in Burkitt lymphoma. PLoS One 2010; 5 (9): pii: e12960.
- Tzankov A, Xu-Monette Z.Y, Gerhard M.V et al. Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Mod Pathol 2014; 27 (7): 958-71.
- Valera A, López-Guillermo A, Cardesa-Salzmann T et al. Grup per l’Estudi dels Limfomes de Catalunya i Balears (GELCAB). MYC Protein Expression And Genetic Alterations Have Prognostic Impact In Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. Haematologica 2013; 98 (10): 1554-62.
- Green T.M, Nielsen O, de S.K et al. High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma. Am J Surg Pathol 2012; 36 (4): 612-9.
- Horn H, Ziepert M, Becher C et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 2013; 121 (12): 2253-63.
- Perry A.M, Alvarado-Bernal Y, Laurini J.A. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab. Br J Haematol 2014; 165 (3): 382-91.
- Dunleavy K, Pittaluga S, Shovlin M et al. Low - intensity therapy in adults with Burkitt's lymphoma. N Engl J Med 2013; 369 (20): 1915-25.
- Hu S, Xu-Monette Z.Y, Tzankov A et al. MYC/BCL2 protein co - expression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high - risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program Study. Blood 2013; 121 (20): 4021-31.
- Green T.M et al, MD Аndersen Cancer Center, 2012. Immunohistochemical detection of MYC protein correlates with MYC gene status in aggressive B-cell lymphoma. Histopathology 2011; 59 (4): 678-8.
- Scott D.W, Mottok A.M, Ennishi D et al. Cell - of - Origin Assignement in Diffuse Large B-cell Lymphoma Determined By Gene Expression in Formalin - Fixed Paraffin - Embedded Tissue Has Prognostic Significance Independent of IPI and MYC/BCL2 Immunohistochemistry. 56th ASH Annual Meeting and Exposition. Abstract book 2014; 124 (21): 1624.
- Аль-Ради Л.С., Барях Е.А., Белоусова И.Э. и др. Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний. Современная Онкология. 2013; 15 (5): 9-10.
- Мисюрина А.Е. Экспрессия MYC и BCL2 у больных диффузной В-крупноклеточной лимфомой. Дис. … канд. мед. наук. М., 2015.